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Advanced Review
Contact-facilitated drug delivery
with Sn2 lipase labile prodrugs
optimize targeted lipid
nanoparticle drug delivery
Dipanjan Pan,1 Christine T.N. Pham,2,3 Katherine N. Weilbaecher,4
Michael H. Tomasson,4 Samuel A. Wickline3 and Gregory M. Lanza3,∗
Sn2 lipase labile phospholipid prodrugs in conjunction with contact-facilitated
drug delivery offer an important advancement in Nanomedicine. Many drugs
incorporated into nanosystems, targeted or not, are substantially lost during cir-
culation to the target. However, favorably altering the pharmacokinetics and vol-
ume of distribution of systemic drug delivery can offer greater efﬁcacy with lower
toxicity, leading to new prolonged-release nanoexcipients. However, the concept
of achieving Paul Erhlich’s inspired vision of a ‘magic bullet’ to treat disease has
been largely unrealized due to unstable nanomedicines, nanosystems achieving
low drug delivery to target cells, poor intracellular bioavailability of endocytosed
nanoparticle payloads, and the substantial biological barriers of extravascular par-
ticle penetration into pathological sites. As shown here, Sn2 phospholipid pro-
drugs in conjunction with contact-facilitated drug delivery prevent premature
drug diffusional loss during circulation and increase target cell bioavailability.
The Sn2 phospholipid prodrug approach applies equally well for vascular con-
strained lipid-encapsulated particles and micelles the size of proteins that pene-
trate through naturally fenestrated endothelium in the bonemarrow or thin-walled
venules of an inﬂamed microcirculation. At one time Nanomedicine was consid-
ered a ‘Grail Quest’ by its loyal opposition and even many in the ﬁeld adsorbing
the pains of a long-learning curve about human biology and particles. However,
Nanomedicine with innovations like Sn2 phospholipid prodrugs has ﬁnally made
‘made the turn’ toward meaningful translational success. © 2015 The Authors. WIREs
Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc.
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INTRODUCTION
Nanomedicine offers approaches to recalcitrantmedical problems by providing tools to detect
and characterize pathology based on the unique
expression of cell surface biosignatures as well as to
deliver therapeutic compounds more specifically to
such lesions using the same platform technology, i.e.,
so called theranostic agents. Among the more effec-
tive class of theranostic agents reported to date are the
lipid-based particles, including liposomes, micelles,
and emulsions. Their success has been derived from an
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inherently high biocompatibility associated with phos-
pholipids, a general ease of lipid functionalization,
and their ‘soft’ compliant three-dimensional (3D)
morphology.
Therapeutic compounds are easily incorporated
into lipid-based particles (i.e., liposomes, micelles, or
emulsions) within the membranes or core, which may
be aqueous or ‘oil’ or even lipophiles. A well-known
nontargeted example is Doxil™, a pegylated liposo-
mal formulation.1 Doxil elimination follows a typical
bi-exponential curve characterized by a rapid distri-
bution phase with a 2-h half-life and a much slower
beta-elimination rate (45 h t1/2). Incorporation of
the Adriamycin into the aqueous phase of liposomes
decreased the volume of distribution in patients to 4L
from 254L for free drug.1 The constrained volume
of distribution and extended circulatory half-life
markedly improved the efficacy of doxorubicin over
free drug. Abraxane, a nontargeted paclitaxel emul-
sion nanoparticle, improved the clinical effectiveness
of paclitaxel over the original Cremophor EL formu-
lation by allowing more rapid infusion rates without
premedication and by increasing the maximum toler-
ated dose.2 Clearly, particulate encapsulation of drugs
can provide unique attributes that improve clinical
utility.
The success of Doxil, the advent of monoclonal
antibody technology, and Paul Erhlich’s, Nobel laure-
ate 1908, inspired vision of a ‘magic bullet’ to treat
disease fueled the era of targeted drug delivery based
on particles that continues robustly today. However, it
was soon recognized that the internalization of thera-
peutic compounds through ligand (antibody)-targeted
particles generally passed through an endosomal
compartment, which diminished the effectiveness
of the drug in comparison to the same exposure of
free drug to the cell surface.3 Subsequently, investi-
gators probed innumerable approaches to overcome
endosomal-related losses of therapeutic cargoes
of drugs, oligonucleotides, and proteins. Cationic
cell-penetrating peptides, such as Tat (transactiva-
tor of transcription) were studied as a mechanism
to enhance intracellular delivery.4 However, these
cationic peptides interact with cell-associated gly-
cosaminoglycans and payloads are subsequently
internalized by and lost to endocytosis. Arginine-rich
CPPs coupled directly to peptide nucleic acids (PNA)
or phosphorodiamidate morpholino oligomers (PMO)
have found improvement at noncytotoxic doses with-
out endosomolytic agents,4 but the same is not found
for cationic nanoparticles.5 In the context of siRNA
and gene delivery, effective delivery of the nucleic
acid-based therapy from endosomes to the nucleus
has received considerable scientific attention with
some promising successes.6–25
Contact-Facilitated Drug Delivery
In contradistinction to the investigators seeking to
internalize particles into cells for drug delivery, we
have pursued a novel approach to targeted drug deliv-
ery and termed it ‘contact-facilitated drug delivery’
(CFDD).26 CFDD refers to the transfer of bound
nanoparticle lipid surfactant components into the
outer leaflet of the target cell membrane. This is a
slow second-order process dependent upon the persis-
tent interaction of the nanoparticle with target mem-
brane surfaces. Casual interactions of lipid encapsu-
lated nanoparticles in circulation with other cell sur-
faces have no significant consequence noted to date.
Figure 1 illustrates the transfer of rhodamine-coupled
phosphatidylethanolamine, a membrane marker, to
the outer and inner membranes of a C32 cell in
culture.27 Close examination (inset) shows the literal
streaming of the fluorescent phospholipid onto the cell
surface. Electron microscopic examination captured
the hemifusion complexation of the monolayer of a









FIGURE 1 | Contact-facilitated drug delivery illustrated with rhodamine PFOB nanoparticle bound to C32 melanoma cell (transfected with Rab
GFP endocytic markers). (Reprinted with permission from Refs 26 and 27. Copyright 2002 and 2008)
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FIGURE 2 | SEM showing PFOB nanoparticle hemifusion complex to
C32 melanoma cell. (Reprinted with permission from Ref 28. Copyright
2009)
the bilayer of target cell membrane (Figure 2).28
In effect, theranostic nanoparticles deliver a ‘kiss of
death’ without the requisite cellular internalization of
the nanoparticles or escape of the drug payload from
an endosomal compartment.
CFDD proved effective in vivo for delivery
of antiangiogenic drugs, particularly fumagillin in
combination with MR angiogenesis imaging using
𝛼v𝛽3-targeted PFC nanoparticles. For example, in
the Vx2 syngeneic adenocarcinoma tumor model
𝛼v𝛽3-targeted PFC nanoparticles delivering native
fumagillin (0.049mg/kg) in three serial minute doses,
greater than 10,000-fold reduction in the systemic
TNP-470 dose, a water soluble analogue, used in
human clinical studies dramatically reduced tumor
development and angiogenesis, which was clearly
revealed by 3D reconstruction of the tumors and
their angiogenic maps created with the same platform
technology (Figure 3(a)).29 Similarly, in hyperlipi-
demic NZW rabbits with early aortic atherosclerosis,
𝛼v𝛽3-targeted nanoparticles provided an MR-based
estimate of the overall plaque burden as reflected by
expanded neovascularity, delivered effective fumag-
illin antiangiogenic therapy, and provided quantitative
follow-up of treatment response (Figure 3(b)).30 More
recently, in the K/BxN mouse model of inflammatory
arthritis, which expresses the T-cell receptor trans-
gene KRN and the MHC class II molecule A(g7),
𝛼v𝛽3-targeted fumagillin nanoparticles administered
serially decreased arthritic score, ankle thickness,
inflammation, proteoglycan depletion, and angio-
genesis (Figure 3(c)).31 In each example, the dose
of fumagillin was well below the serial dosages
of TNP-470 (30mg to 60mg/kg), used in similar
applications. Importantly, TNP-470 at therapeutic
doses, particularly in cancer patients, was associated
with neurocognitive deficits,32–34 which could be
eliminated by targeted nanotherapy.
However, closer examination of these preclin-
ical Nanomedicine results indicated that increased
dosages, both in terms of drug payload per parti-
cle and drug dose per animal, were required as the
pathologic intensity of the disease model increased.
Moreover, other hydrophobic membrane dissolved
drugs, such as paclitaxel, were rapidly lost from the





Targeted Fumagillin versus Control
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Arthritis Score Chg. Paw Thickness
FIGURE 3 | (a) Three-dimensional MR angiogenesis maps of control and integrin-targeted fumagillin NP in Vx2 model. (b) Angiogenesis contrast
before and 1week after a fumagillin or control NPs in hyperlipidemic rabbits. (c) Decreased arthritic score and ankle thickness following targeted
fumagillin in the K/BxN model of inﬂammatory arthritis. (Reprinted with permission from Refs 29–31. Copyright 2008, 2006, and 2009)
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stable in the vial with limited release during in vitro
dissolution studies.26 In vivo pharmacokinetic studies
simultaneously tracking the perfluorocarbon (PFC)
core, the lipid-conjugated peptidomimetic homing
ligand, and a lipid-conjugated paramagnetic chelate
in rodents showed that the lipid anchored-chelate and
integrin homing ligand tracked closely with the clear-
ance of PFC from the blood, indicating that these com-
ponents of the nanoparticles were intact. However,
fumagillin35 or paclitaxel (unpublished) dissolved into
the membranes clearedmuch faster than the PFC, indi-
cating their rapid premature diffusion from the parti-
cle surface into the plasma and extravascular space.
An initial approach to overcome this problem
was to couple drugs, such as paclitaxel, to the amine
of phosphatidylethanolamine, analogous to the pep-
tidomimetic homing ligand and paramagnetic chelate,
using esterase labile intervening linkages of differ-
ent length. In a series of unpublished experiments,
these paclitaxel prodrugs incorporated stably into the
nanoparticle surfactant membrane and were stable
in circulation, but intracellular bioavailability of the
drug was ineffective after binding to the target in vitro
and in vivo. In hindsight, this poor result could have
been anticipated, since we previously noted poor cellu-
lar internalization of compounds with large phospho-
lipid head group modifications, such as paramagnetic
DOTA-chelates that were used to impart r1 relaxiv-
ity for molecular imaging. Gadolinium mass balance
studies showed that the lanthanide-chelate complex
was liberated rapidly from the lipid anchor, likely by
phospholipase D, and bioeliminated through urine.
Although the use of exogenous energy, such as ultra-
sound, could be applied to force these compounds
and particles into the cell endosomal compartment,27
the preferred approach to drug delivery remained the
‘contact facilitated mechanism’.
The concept of a phospholipid prodrug was con-
sidered as a novel means to couple the active pharma-
ceutical ingredient (API) through the Sn2 acyl position
(i.e., stereospecific numbered hydroxyl group of the
second carbon of glycerol) and retain the advantages
of CFDD. This compound could stably self-assemble
into the phospholipid surfactant membrane of parti-
cles positioning the drug in a protective hydropho-
bic environment during circulatory transit to the tar-
get site. Once docked to a cell surface receptor,
contact-mediated streaming of the phospholipid pro-
drug into the outer leaflet of the target cell membrane
would be facilitated. Translation of the lipid-prodrug
from the outer lipid leaflet into the inner lipid leaflet
would encourage rapid distribution of the prodrug
throughout the intracellular membranes and active
drug liberation by target cell phospholipase(s).
PHOSPHOLIPID SN2 PRODRUGS
WITH LIPOSOMES
Phospholipases A2 (PLA2) is part of a super family
of enzymes that catalyze the hydrolysis of the Sn2
ester bond in a variety of phospholipids releasing a
free fatty acid and a lysophospholipid. These enzymes
are classified as five major types: secreted low molec-




factor (PAF) acetylhydrolases, and lysosomal PLA2s.
36
The hydrolysis of the Sn2 ester bond represents the
first step in a pathway to many second messengers,
e.g., the conversion of liberated arachadonic acid into
eicosanoids, which exert a wide range of physiological
and pathological effects. In endothelial cells, multiple
family members of different types of phospholipases
are present thereby creating a rich repertoire of poten-
tial activating agents within target cells. Moreover,
beyond these known types of lipases in endothelial
cells, additional serine hydrolases (or other hydro-
lases) are present, which could also hydrolyze prodrug
to active drug in target cells.
Although the concept of Sn2 phospholipid pro-
drugs had never been considered for targeted drug
delivery associated with CFDD, precedence for the
formation of Sn2 phospholipid prodrugs was initially
reported by David Thompson et al.37 in the context
of triggered release mechanisms. Later Thomas Lars
Andresen and colleagues38–48 pursued an approach to
deliver chemotherapeutics as Sn2 prodrugs via untar-
geted liposomes. They anticipated that increased lib-
eration of phospholipases by cancers would trigger
release of the compounds in the proximity of a tumor
increasing the local drug bioavailability. The effec-
tiveness of this approach was modest and further
enhancement by utilizing a thermosensitive untargeted
prodrug liposome with exogenous heating was only
marginally better.38 Importantly, these investigators
noted that nonpegylated liposomes, which are highly
susceptible to intravascular clearance and destruction,
were more resistant to PLA2 drug liberation than the
more commonly used stealth or pegylated liposomes.
Their data suggested that pegylation of liposomes to
extend intravascular circulation undesirably predis-
posed the vesicles to premature drug release by PLA2.
They further showed that the efficacy of the liposo-
mal Sn2 prodrugs to liberation by secretory phos-
pholipases was dependent on water accessibility to
the bond, which was less available for the synthetic
ether-lipid prodrugs than for natural lipids. Pegyla-
tion enhanced water penetration and enzyme access
to the bond. Targeted PFC nanoparticles or nanoemul-
sions and other lipid micelle particles to be discussed
subsequently were adequately stable in vivo without
88 © 2015 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc. Volume 8, January/February 2016
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pegylation. The reduced water accessibility of the Sn2
prodrug was highly desirable for preventing prema-
ture release or metabolism until the ligand-mediated
binding to the target cell and CFDD ensued.
Other investigators considered phospholipid
prodrugs for improved oral delivery of indomethacin
and valproic acid.49,50 In those studies, Sn2 phospho-
lipid conjugates were utilized to affect oral controlled
release of drugs by continuous degradation of the
phospholipid prodrug within the intestine. Unfor-
tunately, oral administration of the indomethacin
Sn2 prodrug decreased the total amount of drug
absorbed in comparison to the administration of
free indomethacin, although it smoothed the plasma
concentration versus time profile curve, delayed Tmax
and lowered Cmax.
50 Intravenous administration of
the prodrug in untargeted liposomes further reduced
the bioavailability of the APIs relative to oral admin-
istration of the phospholipid prodrug or the free drug.
Importantly, direct attachment of indomethacin to
the Sn2 ester completely blocked PLA2 hydrolysis
activity, while insertion of short spacers between the
drug and the ester bond greatly improved activity.
Mitomycin C, an antibiotic and broad-spectrum
cytotoxic agent, with a notoriously narrow therapeu-
tic window, was studied as a lipophilic prodrug for use
in pegylated liposomes.51–53 In contradistinction to
the Sn2 ester linkage pursued by others, the drug was
coupled through a disulfide bond that remained stable
within circulating pegylated liposomes. This approach
takes advantage of an abundance of reducing agents
within tumors and their microstroma to liberate the
API. Mitomycin-C prodrug liposomes had reduced
toxicity and superior efficacy when compared to free
mitomycin C in ectopic rodent xenograft tumor mod-
els. The prodrug liposomes were more effective than
chemotherapeutic comparators, including irinotecan
and gemcitabine, in gastrointestinal and pancreatic
rodent models. As expected, these liposomal drug
formulations had virtually complete prodrug incor-
poration into the lipid bilayer membranes during





As reported by others, fumagillin is an antiangio-
genic agent specific for proliferating endothelial cells.
Fumagillin can inhibit the formation of angiogenic
vessels by inhibiting methionine aminopeptidase.
Although fumagillin was isolated from the fungal
organism Aspergillus fumigatus, its water soluble
clinical analog, TNP-470 was produced semi synthet-
ically. TNP-470 was found to be effective in rodents
but possessed only anecdotal effectiveness in the
clinic at the high doses required. At clinical dosages,
TNP-470 was associated with numerous toxicities,
including neurocognitive dysfunction.34,54,55 Fumag-
illin, incorporated into the phospholipid surfactant of
nanoparticles for targeted antiangiogenesis therapy,
can be used at a much lower and safer dosages.29,30,56
Despite promising in vivo results, the ‘drugabil-
ity’ of native fumagillin is inherently compromised
by photochemical instability associated with a con-
jugated decatetraenedioic tail, which is known to
undergo rapid degradation even in day light. Fur-
thermore, the presence of two chemically reactive
epoxide rings at the active site makes this compound
highly vulnerable towards an acidic environment,
light and other drastic conditions. Pharmacokinetic
studies demonstrated that hydrophobic drugs, such
as fumagillin, stably incorporated into the phospho-
lipid surfactant of perfluorocarbon nanoparticles
during dissolution studies were rapidly lost and likely
metabolized during particle circulation in vivo.35 To
address this, an Sn2 fumagillin prodrug (Fum-PD)
was envisioned and the compound was synthesized in
a straightforward way in two-steps involving saponifi-
cation of fumagillin dicyclohexylamine salt to fumag-
illol and a subsequent esterification with oxidized lipid
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
(PAzPC) (Figure 4).35
Recently, the antiangiogenesis efficacy of
𝛼v𝛽3-Fum-PD nanoparticles was visualized in vivo
using a novel phospholipid-encapsulated copper
oleate in oil nanoparticle (CuNP) and photoacoustic
microscopic imaging (PA) of neovasculature formed
in a subcutaneous Matrigel™ rodent model.57
Mice implanted with Matrigel™ 18days previously
received 𝛼𝜈𝛽3-CuNPs, nontargeted CuNPs, or 𝛼𝜈𝛽3-
CuNP preceded by 10min with a competitive dose
𝛼𝜈𝛽3-oil only NPs (1:1). As seen in Figure 5, at 0min,
forming vascular tubules were observed by the inher-
ent PA contrast imparted by erythrocyte hemoglobin.
Following 𝛼𝜈𝛽3-CuNP injection, numerous incomplete
vascular sprout offshoots largely devoid of erythro-
cytes were noted. These sprouts were previously
characterized to be nonpolarized immature endothe-
lial cells (𝛼𝜈𝛽3
+, Tie-2−, and CD31+) as opposed to
formed microvessels with polarized endothelium,
which were 𝛼𝜈𝛽3
−, Tie-2+, and CD31+.58 The for-
mation of the angiogenic shoots depicted an early
evolution stage of a dense and irregular neovas-
culature. Animals given nontargeted-CuNPs had
very little change in PA signal with minimal passive


















































FIGURE 4 | Schematic representation of contact-facilitated drug delivery mechanism with Sn2 lipase labile fumagillin prodrug inserted into the
lipid membrane of a PFC nanoparticle. Ligand tethering of the nanoparticle to the target cell support the formation of a hemifusion complex between
the two membrane surfaces. Translation of the Fum-PD into the inner leaﬂet of the target cell membrane leads to its distribution through the cell
except the mitochondria. Regioselective enzymatic cleavage at the Sn2 site by phospholipase (such as phospholipase A2, PLA2) liberates the drug
into the cytosol. (Reprinted with permission from Ref 63. Copyright 2012)
accumulation affording slight blood pool enhance-
ment. In the competition group, very little change in
the PA signal from the vascular tubules or sprouts was
observed. Pretreatment with 𝛼𝜈𝛽3-targeted NPs com-
prising oil core (no Cu oleate) blocked the receptors
to 𝛼𝜈𝛽3-CuNP binding and even precluded significant
passive blood pool accumulation.
𝛼𝜈𝛽3-CuNPs incorporating Fum-PD within the
phospholipid membrane were administered on days
11 and 15 post Matrigel™ implant. At baseline on
day 18, the amount of neovasculature observed by
PA imaging was sparse, similar to that observed in
the other groups. Following 𝛼𝜈𝛽3-CuNP injection,
there was negligible sprout enhancement at 170min.
Blood vessel PA signal was similar to that measured
in the nontargeted CuNP group. ‘Pruning’ of neovas-
culature was first suggested by Dr. Rakesh Jain in a
visionary manner; but in this study, the concept was
visually apparent with Fum-PD and PA microscopic
imaging.59–61
𝛼v𝛽3-Fum-PD Nanoparticles Suppress
Inflammation in the KRN Model of Arthritis
In the K/BxN model of inflammatory arthritis, pas-
sive transfer of K/BxN serum into mice is used
to induce a polyarticular inflammatory arthritis
resembling rheumatoid arthritis (RA).62 Using this
model, serial i.v. injections of 𝛼v𝛽3-Fum-PD NP
after K/BxN serum transfer, in mice with clearly
established arthritis, significantly attenuated disease
progression at doses eightfold lower than that previ-
ously reported using native fumagillin (0.3mg/kg vs
2.4mg/kg).31,63 By contrast, inflammation progressed
rapidly and unabated in the group of mice that
received 𝛼v𝛽3-Ctrl NP (Figure 6). In addition to clin-
ical scores, histologic examination of arthritic paws
revealed that 𝛼v𝛽3-Fum-PD NP limited inflammatory
leukocyte recruitment to the inflamed paws and pro-
tected against bone erosions and cartilage damage
(Figure 6). More importantly, joint-associated inflam-
matory biomarkers VCAM-1 and ICAM-1 and the
90 © 2015 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc. Volume 8, January/February 2016
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Targeted
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Normalized PA amplitude
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(a) (c) (e) (g)
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0 min 0 min
Non-targeted Competition Fum-PD
FIGURE 5 | In vivo PA images of the MatrigelTM plug area implanted in four groups of mice at 18 days using 𝛼v𝛽3-CuNPs. (a, b) Targeted CuNPs
group. The enhanced neovasculature by Cu Oleate NPs are marked by arrows in (b). (c, d): Nontargeted CuNPs group. (e, f) Competition group: mice
received a competitive dose 𝛼v𝛽3-oil only NP (1:1) 10min before 𝛼v𝛽3-CuNPs. (g, h) Fum-PD group: mice received 𝛼v𝛽3-CuNPs with Fum-PD 11 and
15 days after the MatrigelTM implantation then 𝛼v𝛽3-CuNPs w/o fum-PD on day 18 for PA imaging. For all PA images, laser wavelength= 767 nm.
(Reprinted with permission from Ref 57. Copyright 2015)
major pro-inflammatory cytokines and chemokines
(IL-1𝛽, IL-6, MCP-1, and TNF-𝛼) were all diminished
with 𝛼v𝛽3-Fum-PD NP treatment relative control NP
injections. While fumagillin is well known to impact
the proliferation of neovascular endothelial cells, the
direct impact of this mycotoxin on nonendothelial
cell types is negligible.64,65
Follow-up studies presented evidence that
Fum-PD nanotherapy indirectly suppresses inflamma-
tion in K/BxN arthritis through the local production
of endothelial nitric oxide (NO). Fum-PD-induced
NO modulated macrophage inflammatory response
through AMP-activated protein kinase (AMPK).
NO-induced AMPK activation decreased mammalian
target of rapamycin (mTOR) activity and increased
autophagic flux, as evidenced by p62 depletion and
increased autolysosome formation in vivo. Increased
macrophage autophagy flux was associated with
degradation of IkappaB kinase (IKK), suppres-
sion NF-𝜅B-p65 signaling pathway and ultimately
decreased inflammatory cytokine release.66
𝛼v𝛽3-Fum-PD NP Therapy Enhances
the Effectiveness of Methotrexate
Methotrexate (MTX) is commonly used to treat
rheumatoid arthritis (RA) but the onset of clinical
benefit is delayed by weeks and the therapeutic
response is seldom complete. We have previ-
ously demonstrated that native fumagillin NP in
combination with MTX led to significantly improved
and sustained response that could not be achieved
with either agent alone.67 To corroborate this find-
ing, a combination 𝛼v𝛽3-Fum-PD NP and MTX was
administered to mice using the K/BxN serum transfer
model. 𝛼v𝛽3-Fum-PD NP was given as single treat-
ment (x1) on day 2 after K/BxN serum transfer and
MTX was given on days 3, 5, and 7. The combination
of 𝛼v𝛽3-Fum-PD NP (1X)+MTX produced a 55%
reduction in clinical disease indices by day 9. Of note,
the combination of 𝛼v𝛽3-Fum-PD NP given twice (on
days 2 and 4)+MTX (on days 3, 5, and 7) led to fur-
ther improvement in disease activity (∼60% sustained
reduction) over the 9-day study (data not shown). The
improvements in disease activities with the combina-
tion 𝛼v𝛽3-Fum-PD NP (x1)+MTX were greater than
the responses observed with 𝛼v𝛽3-Ctrl NP+MTX
while treatment with 𝛼v𝛽3-Fum-PD NP (x1) without
MTX did not lead to sustained clinical response.
Mice treated with the combination of 𝛼v𝛽3-Fum-PD
NP+MTX also lost less body weight during the study
and rebounded to pretreatment weight by day 9, while
the weight loss among animals in all other experimen-
tal groups remained below baseline. The combination
of 𝛼v𝛽3-Fum-PD NP+MTX suppressed the influx of
inflammatory cells into arthritic paws by approxi-
mately 90%, which was an additional 30% reduction
in inflammatory leukocytes recruitment seen in the
𝛼v𝛽3-Ctrl NP+MTX group. Dual 𝛼v𝛽3-Fum-PD











































































































































FIGURE 6 | 𝛼v𝛽3-Fum-PD NP suppressed inﬂammatory arthritis in the KRN model. Targeted particle with and without drug were administered on
days 2, 3, and 4 (arrows). Changes in ankle thickness (a), arthritic score (b), and body weight (c) were monitored daily. Histology on day 7 for
inﬂammatory cell number per high power ﬁeld (HPF; d, e, j), erosions (f, g, k), and proteoglycan depletion (h, i, l) *P < 0.05, **P < 0.01,
***P < 0.0001. (Reprinted with permission from Ref 63. Copyright 2012)
NP-MTX therapy was also superior to other
treatments in preventing bone erosions and in
preserving cartilage integrity (Figure 7).
These experiments revealed that the lipase-labile
Sn2 Fum-PD was bioequivalent to native fumag-
illin when incorporated into integrin-targeted PFC
nanoparticles alongwith improved photochemical sta-
bility and nanoparticle surfactant retention. Antian-
giogenic therapies are typically used as adjuvant ther-
apies for acute benefit to accelerate or enhance the effi-
cacy of a primary therapy. In this series of experiments,
single dose 𝛼v𝛽3-Fum-PD NP significantly enhanced
the efficacy of MTX.
While fumagillin is an established antiangiogenic
compound, other drugs, such as taxanes used at lower
dosages also have potent antiangiogenesis properties.
A brief pilot study testing a lipase-labile Sn2 paclitaxel
prodrug given serially (on days 2, 3, and 4), analo-
gous to previous Fum-PD NP studies,63 demonstrated
markedly improved effectiveness against arthritis
manifestation in the K/BxN model, virtually suppress-
ing all clinical indices during this entire study interval
(Figure 8). These results were followed by further
evaluation of 𝛼v𝛽3-docetaxel-prodrug in the very
aggressive Vx2 rabbit squamous carcinoma model.
Docetaxel
Despite extensive clinical research on the effects and
benefits of antiangiogenesis therapy in cancer and
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FIGURE 7 | 𝛼v𝛽3-Fum-PD NP (1X) in combination with MTX suppressed inﬂammatory arthritis in the KRN mouse model. 𝛼v𝛽3-Fum-PD NP or
𝛼v𝛽3-control NP were given on day 2 (n= 5/group) and changes in ankle thickness (a) arthritic score (b) and body weight (c) were monitored daily.
Histology on day 9 revealed signiﬁcant beneﬁt for inﬂammatory cell number/HPF (d), erosions (e), and proteoglycan depletion (f).*P < 0.05.
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FIGURE 8 | 𝛼v𝛽3-Paclitaxel-PD NP suppressed inﬂammatory arthritis in the KRN model. Targeted particle with and without drug were
administered on days 2, 3, and 4 (arrows). Changes in ankle thickness (a) and arthritic score (b) were monitored daily ** P < 0.01.
selected other pathologies, virtually all of the work
has centered on vascular endothelial growth factor
(VEGF) inhibition. While VEGF is a clear driver of
angiogenesis, it elicits pleotropic effects and is not
solely responsible for neovascularization.68 Moreover,
VEGF is produced by a variety of cell types, making
effective blockade of the growth factor challenging.
Typically, relatively high dosages of medicants are
used clinically and these treatments have well known
side effects.69
Paclitaxel is a cytoskeletal drug that interacts
with tubulin to corrupt mitotic spindle assembly, chro-
mosome segregation, and cell division by inhibiting
microtubule disassembly. As a consequence, chro-
mosomes are unable to achieve proper metaphase
configuration and mitotic progression is blocked.
The inability to complete cell division promotes
apoptosis or reversion to a quiescent G0-phase of
the cell cycle. The rarity of paclitaxel, initially iso-
lated from the Pacific yew, led to synthetic chem-
ical pathway development and the emergence of
docetaxel, a close chemical analog of the index
compound with similar biological properties. Tax-
anes have found clinical applications as a cytotoxic
cancer chemotherapeutic70 as well as stent-delivered
inhibitors of restenosis following angioplasty.71 In
Nanomedicine, the hydrophobic nature of paclitaxel
has favored its incorporation into many nanoparticle
formulations, including into the phospholipid outer
membrane of PFC nanoparticles.
Lipid-encapsulated perfluorocarbon nanoparti-
cles have been targeted to a myriad of epitopes for
diagnostic imaging and site-specific drug delivery for
applications in atherosclerosis, restenosis, cancer, and
RA.31,67,72,73 Preliminary studies in the Vx2 rabbit
squamous carcinoma model showed that paclitaxel
incorporated into the outer lipid membrane of PFC
nanoparticles was not effective for antiangiogenesis.
Subsequent pharmacokinetic studies revealed the lack
of efficacy to be related to significant drug loss in circu-
lation with the premature release of the taxane occur-
ring quicker and to a greater extent than for the more
hydrophobic fumagillin.
Docetaxel (Dxtl) has a low solubility in
water (<0.1 μg/mL) and from the synthetic stand
point, chemistries involving esterification of the
2′-hydroxyl group, which is the most reactive of
the all the available hydroxyl groups, are feasible.
Conventional methods of protecting a hydroxyl
group, such as esterification, can be utilized to
protect this 2′-hydroxyl group, while leaving the
hydroxyl groups at the positions 7 and 10 free for
reaction. For the synthesis of docetaxel prodrug
(Dxtl-PD), carbodiimide/4-dimethylaminopyridine
(EDCI/DMAP) was the most efficient coupling effi-
cient approach and produced the desired compound in
78% yield. The compound was isolated and purified
by preparative thin layer chromatography (prep-TLC)
and the structure was confirmed by NMR and ESI
MS spectroscopy.74
The retention of the Dxtl-PD in the PFC
nanoparticle during in vitro dissolution over 3 days
in PBS with albumin or human plasma was excellent
with <6% of prodrug released, indicating drug mem-
brane stability.74 These results are in contradistinction
to the rapid release (∼10%/day) of native paclitaxel
from PFC nanoparticles under similar dissolution
conditions.26 Excess phospholipase A2 added to
the incubation medium with Dxtl-PD nanoparticles
produced negligible release of the drug. Furthermore,
incubation of the Dxtl-PD nanoparticles in whole
blood under slow continuous agitation imparted
no passive prodrug transfer to erythrocytes through
transient contact. When free Dxtl-PD was added
to lipase rich plasma, docetaxel was liberated and
differentiated from the parent prodrug. Regioselective
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hydrolysis of the nanoparticle incorporating Dxtl-PD
by PLA2 in vitro required the addition of 2-propranol
to ‘crack’ the particle surfactant and expose the mem-
brane components to the enzyme.Multiple peaks were
observed showing that the Dxtl was hydrolyzed from
the prodrug backbone including baccatin III (m/z 524
[M+Na]), which is a known degradation product in
rats and humans.75,76 These results support the model
that Dxtl-PD is snuggled into the hydrophobic mem-
brane protected from hydrolysis and lipase activation
in blood until the nanoparticle is destabilized, such as
with alcohol or by targeted binding.
The bioequivalence of paclitaxel, paclitaxel pro-
drug, docetaxel, or docetaxel prodrug at 0.5, 1, 5,
10, 50, and 100 μg/mL was studied in angiotensin
II stimulated mouse vascular endothelial cells (2F2B)
following 1 h of exposure with mild agitation.74 No
differences in endothelial proliferation were noted at
24, 48, and 72 h after exposure. The cytotoxicity of
Dxtl-PD incorporated into PFC NPs was compared to
Taxol® in vitro using 2F2B endothelial cell cultures
stimulated with angiotensin II to upregulate activated
𝛼v𝛽3-integrin expression. 𝛼v𝛽3-Dxtl-PDNPs decreased
(P< 0.05) cell proliferation 34% at 96 h compared
with the saline control. The 𝛼v𝛽3-no-drug NPs had
no effect on cell proliferation. At the equivalent low
dose of taxane, Taxol® decreased cell proliferation
less, 8%, which was similar to the controls but not
significantly less than the 𝛼v𝛽3-Dxtl-PD NP (Figure 9).
In a followup experiment using angiotensin
II-stimulated HUVEC cells, cell metabolic activity
responses to docetaxel and Dxtl-PD NP were assessed
at earlier time points: 48, 72, and 96 h. In that
experiment, native docetaxel in methanol added to
the medium was compared with its integrin-targeted
lipase-labile prodrug analog on an equimolar drug
basis. 𝛼v𝛽3-Dxtl-PD NPs, free docetaxel, and 𝛼v𝛽3-no
drugNPs. 𝛼v𝛽3-Dxtl-PDNPs and free docetaxel equiv-
alently decreased (P< 0.05) cell metabolic activity at
48 h compared with 𝛼v𝛽3-no drug NP. The marked
reductions in cell metabolic activity persisted for both
drug forms at 72 and 96 h. These results further sub-
stantiate the comparable bioequivalence of the native
docetaxel and targeted Sn2 lipase-labile prodrug and
suggest that the intracellular enzymatic hydrolysis
requirement to achieve efficacy with Dxtl-PD was not
limiting in the activated HUVEC cells.
The efficacy of the docetaxel Sn2 prodrug incor-
porated into the lipid membrane of 𝛼v𝛽3-targeted PFC
nanoparticles (𝛼v𝛽3-Dxtl-PD NP) was compared in
the Vx2 rabbit tumor model to nontargeted Dxtl-PD
NPs (NT-Dxtl-PD NP) and 𝛼v𝛽3-No Drug NPs. Ani-
mals were serially treated on days 9, 12, and 15 days
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FIGURE 9 | Mouse vascular endothelial cells (2F2B) stimulated with
angiotensin II (1nM) were treated with paclitaxel, docetaxel, paclitaxel
prodrug, or docetaxel prodrug at 0.5, 1, 5, 10, 50, and 100 μg/mL for
1 h. Cultures were monitored for proliferation at 24, 48, and 72 h. No
difference (P =NS) in biopotency of the different taxanes forms was
detected. (Reprinted with permission from Ref 74. Copyright 2014)
a clinical 3T MR scanner (Philips Achieva) using
a high-resolution, T1-weighted, fat suppressed, 3D
gradient echo sequence at baseline and 3 h after
i.v. administration of 𝛼v𝛽3-Gd-DOTA nanoparticles
(1mL/kg), previously characterized and demonstrated
in vivo (Figure 10).77,78
Angiogenesis contrast in the control animals
was concentrated in the tumor periphery with mini-
mal signal enhancement localized to the core, except
for the rare lobulated tumor with an internal seg-
ment of neovascular-rich capsule. 𝛼v𝛽3-Dxtl-PD NPs
substantially decreased (P< 0.05) MR detectable
angiogenesis in the Vx2 tumor model after serial
treatment, as opposed to the negative results achieved
previously with the targeted particles incorporating
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FIGURE 10 | (a) T1w MR images of Vx 2 tumor obtained at baseline and 3 hours after 𝛼v𝛽3-Gd-DOTA NP in animals receiving 𝛼v𝛽3-no drug NP
showing peripheral tumor angiogenesis contrast enhancement false colored in yellow. (b) The same image sequence as panel (a) in Vx2 tumor rabbits
following 𝛼v𝛽3-Dxtl-PD NP. (c) Histogram illustrating marked angiogenesis in the control rabbits rim (tumor peripheral 50%) versus those receiving
Dtxl-PD with or without targeting. Note minimal contrast signal with the tumor core. Marked decrease in contrast in nontargeted (NT) animal group
suggests that the dosage or frequency of treatment was in excess of the therapeutic need with passive entrapment providing adequate
particle-to-endothelium contact to afford signiﬁcant antiangiogenesis. (d) Representative three-dimensional neovascular maps of Vx2 tumor in
control and targeted Dxtl-PD treatment groups. Note asymmetric distribution of conﬂuent neovascular regions in the control rabbit note appreciated
in the treated animal. Blue voxels equate to 𝛼v𝛽3-Gd-DOTA NP contrast enhancement exceeding three standard deviations over baseline.
*P < 0.05,
**P < 0.01. (Reprinted with permission from Ref 74. Copyright 2014)
native paclitaxel. NT-Dxtl-PD NP elicited neo-
vascular suppression similar to 𝛼v𝛽3-Dxtl-PD NP,
suggesting that the passive entrapment of the fre-
quently dosed NT-Dxtl-PD NP provided enough
sustained particle-endothelial cell contact under this
serial regimen to afford prodrug transfer too low
to be differentiated with MR molecular imaging
at 3T. To verify that the antineovascular effect of
the Dxtl-PD NPs observed MR molecular imag-
ing was not attributable to the systemic premature
release of taxane, a separate cohort of rabbits were
implanted with the Vx2 tumor and treated serially
with Abraxane® at an equimolar dose and compared
to an independent saline control. MR molecular
imaging of angiogenesis in this cohort on day 17
revealed no antiangiogenic effect with Abraxane®.
Over this short study, no difference in tumor volume
between any treatment groups was measured.74
Histological assessments of tumor showed that
𝛼v𝛽3-Dxtl-PD NP decreased (P< 0.05) tumor cell pro-
liferation, as assessed by PNCA staining of the lesion,
with the same trend noted for tumor apoptosis. The
higher-sensitivity higher-resolution microscopic data
indicated that targeted delivery of Dxtl-PD was bio-
logically more effective than NT Dxtl-PD treatment,
highlighting both the relative insensitivity of MR
molecular imaging and the high potency of Dxtl-PD
NPs (Figure 11).
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FIGURE 11 | (a) Histogram showing a trend (nonsigniﬁcant [NS], P = 0.2) toward increased apoptosis among Vx2 tumor rabbits receiving
𝛼v𝛽3-Dxtl-PD NP versus controls. (b) Illustrative sections (40×) of Vx2 tumor following TUNEL staining (brown arrows) using a methyl green nuclear
positive reference for tumor area (green arrows). (c) Histogram showing a signiﬁcant (P < 0.05) decrease in proliferation index among Vx2 tumor
rabbits receiving 𝛼v𝛽3-Dxtl-PD NP versus controls. (d) Representative sections (40×) of Vx2 tumor following PCNA staining (brown arrows) using a
methyl green nuclear positive reference for tumor area (green arrows). *P < 0.05. (Reprinted with permission from Rf 74. Copyright 2014)
cMyc–Max Transcription Factor Antagonism
in Myeloma
Multiple myeloma (MM) is amalignancy derived from
a clone of plasma cells, which are terminally dif-
ferentiated B-lymphocytes responsible for antibody
production. As the second most common hemato-
logic malignancy in the United States, MM accounts
for 1% of cancer deaths. While recent therapeu-
tic advances suggest future improvement, the cur-
rent 5-year survival rate in patients with MM is less
than 40%.79 MM is initially responsive to several
classes of chemotherapy, (e.g., proteasome inhibitors,
immunomodulatory drugs [IMiDs], and alkylating
agents), but eventually virtually all patients relapse
and die from progressive disease.
The b-HLHZIP transcription factor c-Myc
(MYC) is a powerful oncogene activated in many
types of cancer, and is a central driver of myeloma
development.80 The expression of MYC increases
with disease stage in MM, and MYC up-regulation
likely plays an important role in the evolution of
MGUS into MM.81 MYC activation is likely to be an
early event in myeloma pathogenesis with MYC rear-
rangement present in about 15% of newly diagnosed
myeloma,79,82 which may be an underestimation of
the prevalence of MYC translocations.83 The role of
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MYC in MM was further indicated in a transgenic
mouse model of myeloma with targeted activation of
MYC in germinal center B-cells.84
In general, transcription factor’s relative posi-
tion downstream as integrators of multiple signal-
ing cascades makes them an attractive therapeutic
target which has been approached through anti-
sense strategies,85 RNA interference,86 and inter-
ference with MYC–MAX dimerization using small
molecules.87 Transformation by MYC is dependent
upon dimerization with the bHLHZIP protein MAX.
MYC–MAX heterodimers bind to E-Boxes in the
vicinity of target genes88 to regulate their expression
and to modulate numerous biological functions.89–91
The difficulty of inhibiting protein–protein or
protein–DNA interactions with small molecules has
made MYC a challenging therapeutic target.92–95
Several small-molecule inhibitors of the MYC–MAX
interaction were developed.87,96–99 However, the
development of these compounds experienced barri-
ers of rapid systemic metabolism, significant toxicity,
poor cancer bioavailability and an inability of the drug
to reach intratumoral inhibitory concentrations.99
Given the potency of some MYC–MAX dimer-
ization antagonists in cell-free assay, a Sn2 phospho-
lipid prodrug nanomedicine strategy was considered
to protect the compound in circulation and deliver it
effectively into the target MM cells. An index com-
pound (10058-F4) was synthesized and modified into
the Sn2 prodrug form100,101 Myc-inhibitor-1 prodrug
(MI1-PD)(Figure 12).37 The cytotoxic activities of the
base compound, MI1, and the prodrug MI1-PD were
evaluated and compared in human (H929 and U266)
and mouse (5TGM1) MM cell lines at concen-
trations ranging from 1.0 nM to 100 μM. MTT
cell viability assay showed that MI1-PD in DMSO
decreased cell viability substantially more (P<0.05)
than MI1 in DMSO on an equimolar basis. Further-
more, MI1-PD induced significant apoptosis in the
three MM cell lines, 92, 91, and 91% of control,
respectively, whereas apoptosis was induced with MI1
was significantly less, 19, 31, and 31%, respectively
(P< 0.05).101
As with all targeted therapies, nanotherapeutic
delivery of MI1-PD is dependent upon the specific
binding of nanoparticle to target cells. In this regard,
the suitability 𝛼v𝛽3-integrin and 𝛼4𝛽1-integrin (VLA-4)
target biomarkers was evaluated in aggressive human
and mouse MM cells. Both integrins showed poten-
tial utility as targets for human MM in culture, but
only 𝛼4𝛽1-integrin was adequately prevalent in the
mouse 5TGM1 line, which was used below for in vivo
study. The 5TGM1 MM is one of a series of trans-
plantable murine myelomas arising spontaneously
in C57BL/KaLwRij mice.102–104 The therapeutic
potential of VLA-4-targeted MI1-PD-containing
NP was evaluated in KaLwRij mice inoculated
intravenously with 5TGM1 cells and distributed
into six groups. Mice were treated intravenously
(50 μL of 20% suspension v/v) with targeted (T) or
nontargeted (NT) PFC (200 nm) or micellar (20 nm)
lipid-encapsulated particles that incorporatedMI1-PD
(D) or no drug (ND) on days 3, 5, 7,10,12, and 14.
The following treatment cohorts were studied 1)
ND/NT 200nm PFC NP; 2) T/ND 200nm PFC NP;
3) T/D 200nm PFC NP; 4) NT/ND 20nm micelles;
5) T/ND 20nm micelles, and 6) T/D 20nm micelles
(Figure 13).101 Disease progression was monitored
by survival and serial measurements of serum para-
protein on day 17. Intravenously administered free
MI1 and free MI1-PD offered no survival bene-
fit for 5TGM1/KaLwRij myeloma mice versus the
DMSO control. The tumor burden as reflected by
serum immunoglobulin was decreased (P<0.05) in
mice treated with targeted MI1-PD NP as compared
to nontargeted no drug NPs regardless of particle
size, however, the best results were obtained with
VLA-4-targeted MI1-PD micelles: (T/D 20: 52 days vs
29 days, P=0.001) (Figure 14).
These results demonstrated a nanomedicine ther-
apeutic approach to MM and for the first time
showed reduced tumor burden in live mice using
a potent MYC–MAX inhibitor. The Sn2 phospho-
lipid prodrug MI1-PD significantly increased drug
potency against myeloma cells in culture compared
with its free drug counterpart, most likely due to
increased cell bioavailability. When incorporated into
lipid surfactant-coated nanoparticles and targeted to
integrins, MI1-PD was most effective against cell lines
strongly expressing the targeted biomarker, and less
potent when receptor expression was low or absent. In
an orthotopic mouse model of disseminated myeloma,
administration of VLA-4-targeted MI1-PD NP con-
ferred significant survival benefit versus nontargeted
and drug-free controls, while neitherMI1 norMI1-PD
provided any survival benefit when administered sys-
temically as free compounds. These data provide
a foundation to reconsider MYC transcription fac-
tor antagonism as a viable therapeutic strategy in
MM and more broadly exemplify the potential of
Nanomedicine approaches utilizing Sn-2 lipase labile
prodrugs to overcome the poor solubility, poor sys-
temic stability, poor biodistribution, or poor bioavail-
ability that plague many therapeutic compounds.
CONCLUSION
Sn2 lipase labile phospholipid prodrugs in conjunc-
tion with CFDD offer an important advancement
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FIGURE 12 | (a) Chemical structures of VLA-4-PEG-phospholipid conjugate, 𝛼v𝛽3-PEG-phospholipid conjugate and MI1-PD. (b) Schematic
representation illustrating nanoparticle (NP) design and lipid monolayer-mediated intracellular release of MYC-inhibitor from MI1-PD. The Myc
prodrug (MI1-PD) from Panel a is represented by circles. The integrin-targeting ligands (VLA-4-PEG-phospholipid conjugate and
𝛼v𝛽3-PEG-phospholipid conjugate) from Panel a is represented by triangles. (A) Anti-Myc NPs are targeted by the homing ligand to myeloma (MM)
cells expressing integrin proteins on their cell surface (represented by V). (B) Proximity induces hemifusion of lipid layers between NP and MM cells.
(C) The MI1-PD in the NP membrane is then exposed to cellular lipases that (D) cleave the phospholipid moiety of the prodrug and release the
anti-Myc moiety into the MM cell.100
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FIGURE 13 | Myc inhibitor 1 (MI1) and MI1 prodrug (MI1-PD) decrease viability and induce apoptosis in myeloma cell lines. (a) MTT assay for cell
viability at 24 h with MI1 and MI1-PD at given concentrations in H929, U266, and 5TGM1 cells. Values are average of three separate experiments in
triplicates and expressed as mean± SD. *P < 0.05. (b) Representative of Annexin V-PE staining of cells for apoptosis following MI1 and MI1-PD
treatment (left and right columns respectively) at given concentrations in H929, U266, and 5TGM1 cells at 24 h. (Reprinted with permission from Ref
101. Copyright 2014)
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FIGURE 14 | Anti-MYC NPs prolong survival in a mouse model of multiple myeloma. (a) MTT studies in 5TGM1 cells at 24 h. (b) The experimental
protocol for the in vivo tumor growth assay. The groups were as follows: (1) ND/NT 200; (2) T/ND 200; (3) T/D 200; (4) NT/ND 20; (5) T/ND 20; and (6)
T/D 20 all injected on days 3, 5, 7, 10, 12, and 14 following the i.v. injections of 5TGM1 cells (day 0) (c, d) SPEP quantiﬁcation of each treatment
groups 3 days after the last injection was given (each dot represents SPEP value for one mouse). (e, f) Kaplan–Meier survival curves of the treated
mice with 20 and 200 nm NPs. (Reprinted with permission from Ref 101. Copyright 2014)
in Nanomedicine. Often drugs incorporated into
nanosystems, targeted or not, are lost during circu-
lation to the target and these systems have morphed
into prolonged release nanoexcipients that favorably
alter the pharmacokinetics and volume of distribu-
tion of drugs yielding greater efficacy and lower toxic-
ity. Sn2 phospholipid prodrugs favorably address pre-
mature drug loss and inadequate target cell bioavail-
ability for lipid-encapsulated nanoemulsions for both
nanomedicines constrained by design to vascular
accessible targets like the neovasculature, as well as
for particles essentially the size of proteins which,
penetrate through naturally fenestrated endothelium,
as found in the bone marrow or inflamed thin-walled
venules of the microcirculation to reach extravascular
targets.
Twenty years ago, the concept of specifically
targeting a particle to any biological marker was con-
sidered a hope. Today, innumerable nanomedicines
accomplish this feat in preclinical animal models.
The prospects for Nanomedicine therapies to address
intractable medical issues, such a MM, have never
been better. Nanomedicine has finally made ‘made the
turn’ toward meaningful success.
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